Results of long-term treatment of osteoporosis with 1 alpha-hydroxyvitamin D3 and calcium.
The results of long-term treatment of osteoporotic patients with 1 alpha-hydroxyvitamin D3 (1 alpha-OHD3) and calcium supplements during periods up to 3 years were evaluated. This treatment showed an increased bone density, especially in patients classified as postmenopausal osteoporis.
D000328:Adult; D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000187:drug effects; D002118:Calcium / Q000097:blood / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D008134:Long-Term Care; D008274:Magnesium / Q000097:blood; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism; D010024:Osteoporosis / Q000188:drug therapy* / Q000201:enzymology; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000097:blood
D006887:Hydroxycholecalciferols; D008903:Minerals; D010281:Parathyroid Hormone; D010710:Phosphates; D003404:Creatinine; D000469:Alkaline Phosphatase; D008274:Magnesium; D002118:Calcium; C008088:alfacalcidol